Aurobindo Pharma is currently trading at Rs. 792.80, up by 9.75 points or 1.25% from its previous closing of Rs. 783.05 on the BSE.
The scrip opened at Rs. 800.00 and has touched a high and low of Rs. 814.30 and Rs. 787.30 respectively. So far 220369 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 967.60 on 10-Aug-2020 and a 52 week low of Rs. 281.15 on 23-Mar-2020.
Last one week high and low of the scrip stood at Rs. 814.30 and Rs. 749.55 respectively. The current market cap of the company is Rs. 46344.81 crore.
The promoters holding in the company stood at 52.01%, while Institutions and Non-Institutions held 36.68% and 11.31% respectively.
Aurobindo Pharma has signed definitive agreement to sell Natrol, a unit of Aurobindo Pharma USA, Inc, to an affiliate of New Mountain Capital to combine with Jarrow Formulas. The all-cash transaction is valued at $550 million (around Rs 4,048 crore). Subject to customary closing conditions and regulatory approvals, the transaction is expected to close by January 2021.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
